These phenotypes could be due to KRAS repressing the interferon regulatory factor 2 (IRF2), leading to high CXCL3 expression and the recruitment of myeloid‐derived suppressor cells to the tumor microenvironment [55]. The gene discussed is IRF2; the disease is neoplasm.